3 June 2025

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation

Hemogenyx Pharmaceuticals plc is pleased to announce that the second patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults.

The treatment was well tolerated and met the trial's predefined initial safety criteria. Encouragingly, early indications of clinical efficacy are evident. The patient will continue to be monitored according to the FDA-approved trial protocol to assess whether the study's secondary endpoints are achieved.

Manufacturing of HG-CT-1 for the treatment of a third patient is currently underway.

The Phase I trial is a dose-escalation study designed to evaluate the safety and tolerability of HG-CT-1. In addition to safety, the trial includes several key secondary endpoints:

- Assessing the efficacy of HG-CT-1 based on AML-specific response criteria
- Evaluating overall survival
- Measuring progression-free survival
- Determining duration of response in patients demonstrating clinical benefit

Data related to these secondary endpoints, including efficacy, durability, and overall clinical outcomes, will be collected over time through continued follow-up of the treated patient. These secondary endpoints are critical for assessing the potential clinical impact of HG-CT-1 in a patient population with limited remaining treatment options.

Further updates will be provided as the trial progresses.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "The successful treatment of the second patient represents a meaningful step forward for both Hemogenyx and for patients battling relapsed or refractory AML. We are encouraged by the favorable safety profile observed to date and by the early signs of efficacy. These results further validate the promise of HG-CT-1 as a novel treatment for one of the most aggressive and intractable forms of leukemia. We remain focused on advancing the clinical development of this therapy to address a critical unmet need, while also building long-term value for our shareholders."

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl	
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow	

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.